The 10 men with severe hemophilia B received a single dose of scAAV2/8-LP1-hFIXco vector, administered through a peripheral vein, in three dose cohorts (low dose: 2×10 11 vector genomes [vg]/kg ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) has presented new five-year data from its pivotal Phase III trial of ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

An innovative and affordable point-of-care test kit has been developed by the National Institute of Immunohaematology to diagnose genetic bleeding disorders like hemophilia A and Von Willebrand ...

Hemophilia is a rare genetic disorder that affects the blood's ability to clot, impacting around 1.1 million people globally. Hemophilia A is caused by a deficiency in clotting Factor VIII, while ...